Orally effective iron chelators for the treatment of iron overload disease: the case for a further look at pyridoxal isonicotinoyl hydrazone and its analogs.

Suppr

超能文献

作者信息

Richardson D R, Ponka P

出版信息

J Lab Clin Med. 1998 Oct;132(4):351-2. doi: 10.1016/s0022-2143(98)90049-x.

DOI:10.1016/s0022-2143(98)90049-x

PMID:9794707

Abstract

摘要

相似文献

Orally effective iron chelators for the treatment of iron overload disease: the case for a further look at pyridoxal isonicotinoyl hydrazone and its analogs.

J Lab Clin Med. 1998 Oct;132(4):351-2. doi: 10.1016/s0022-2143(98)90049-x.

Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease.

J Lab Clin Med. 1998 Apr;131(4):306-15. doi: 10.1016/s0022-2143(98)90180-9.

Pyridoxal isonicotinoyl hydrazone (PIH) and its analogs as protectants against anthracycline-induced cardiotoxicity.

Hemoglobin. 2008;32(1-2):207-15. doi: 10.1080/03630260701680276.

Pyridoxal isonicotinoyl hydrazone. Effective iron chelation after oral administration.

Ann N Y Acad Sci. 1990;612:315-26. doi: 10.1111/j.1749-6632.1990.tb24319.x.

Pyridoxal isonicotinoyl hydrazone: an effective iron-chelator after oral administration.

Semin Hematol. 1990 Apr;27(2):112-6.

Iron chelation therapy.

Curr Hematol Rep. 2005 Mar;4(2):110-6.

Biliary iron excretion in rats following treatment with analogs of pyridoxal isonicotinoyl hydrazone.

Blood. 1998 Jun 1;91(11):4368-72.

Pyridoxal isonicotinoyl hydrazone and its analogues.

Adv Exp Med Biol. 2002;509:205-29. doi: 10.1007/978-1-4615-0593-8_11.

Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal.

J Lab Clin Med. 1981 Jul;98(1):99-108.

PCTH: a novel orally active chelator for the treatment of iron overload disease.

Hemoglobin. 2006;30(1):93-104. doi: 10.1080/03630260500455367.

引用本文的文献

Encapsulation and Biological Activity of Hesperetin Derivatives with HP-β-CD.

Molecules. 2023 Sep 30;28(19):6893. doi: 10.3390/molecules28196893.

3-Chloro-'-(2-hydroxybenzylidene) benzohydrazide: An LSD1-Selective Inhibitor and Iron-Chelating Agent for Anticancer Therapy.

Front Pharmacol. 2018 Sep 7;9:1006. doi: 10.3389/fphar.2018.01006. eCollection 2018.

A multifunctional, light-activated prochelator inhibits UVA-induced oxidative stress.

Bioorg Med Chem Lett. 2015 Nov 1;25(21):4843-4847. doi: 10.1016/j.bmcl.2015.06.048. Epub 2015 Jun 18.

Potent antimycobacterial activity of the pyridoxal isonicotinoyl hydrazone analog 2-pyridylcarboxaldehyde isonicotinoyl hydrazone: a lipophilic transport vehicle for isonicotinic acid hydrazide.

Mol Pharmacol. 2014 Feb;85(2):269-78. doi: 10.1124/mol.113.090357. Epub 2013 Nov 15.

Anti-plasmodial activity of aroylhydrazone and thiosemicarbazone iron chelators: effect on erythrocyte membrane integrity, parasite development and the intracellular labile iron pool.

J Inorg Biochem. 2013 Dec;129:43-51. doi: 10.1016/j.jinorgbio.2013.08.007. Epub 2013 Aug 26.

Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

BMC Med Genomics. 2009 Jan 8;2:2. doi: 10.1186/1755-8794-2-2.

Ceruloplasmin protects injured spinal cord from iron-mediated oxidative damage.

J Neurosci. 2008 Nov 26;28(48):12736-47. doi: 10.1523/JNEUROSCI.3649-08.2008.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验